Phase I trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer
2005 · British Journal of Cancer · 117 citations
https://doi.org/10.1038/sj.bjc.6602644
T
Taketo Yamaguchi
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
256
Papers
6.9K
Citations
42
h-index
118
i10-index
Taketo Yamaguchi is an academic researcher from Funabashi Central Hospital. The author has contributed to research in topics: Pancreatic and Hepatic Oncology Research & Gastric Cancer Management and Outcomes & Gallbladder and Bile Duct Disorders. The author has an h-index of 42, co-authored 218 publications.
Papers by this author
worksPhase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer
2006 · British Journal of Cancer · 114 citations
https://doi.org/10.1038/sj.bjc.6603168
TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial)
2018 · European Journal of Cancer · 32 citations
https://doi.org/10.1016/j.ejca.2018.10.004
Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer
2017 · Journal of Cancer Research and Clinical Oncology · 30 citations
https://doi.org/10.1007/s00432-017-2349-y
Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer
2017 · British Journal of Cancer · 26 citations
https://doi.org/10.1038/bjc.2016.436
Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study
2017 · ESMO Open · 16 citations
https://doi.org/10.1136/esmoopen-2016-000151
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat